PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE2
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
- Status
- UNKNOWN
- Phase
- NA
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
- Status
- UNKNOWN
- Phase
- NA
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
- Status
- UNKNOWN
- Phase
- PHASE2
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- Status
- RECRUITING
- Phase
- PHASE2
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE2
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
- Status
- TERMINATED
- Phase
- PHASE2
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE3